Skip to main content

Toxin-based targeted therapy for malignant brain tumors.

Publication ,  Journal Article
Chandramohan, V; Sampson, JH; Pastan, I; Bigner, DD
Published in: Clin Dev Immunol
2012

Despite advances in conventional treatment modalities for malignant brain tumors-surgery, radiotherapy, and chemotherapy-the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Dev Immunol

DOI

EISSN

1740-2530

Publication Date

2012

Volume

2012

Start / End Page

480429

Location

Egypt

Related Subject Headings

  • Tumor Microenvironment
  • Survival Analysis
  • Recombinant Fusion Proteins
  • Proteomics
  • Prognosis
  • Precision Medicine
  • Molecular Targeted Therapy
  • Immunotoxins
  • Immunology
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chandramohan, V., Sampson, J. H., Pastan, I., & Bigner, D. D. (2012). Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol, 2012, 480429. https://doi.org/10.1155/2012/480429
Chandramohan, Vidyalakshmi, John H. Sampson, Ira Pastan, and Darell D. Bigner. “Toxin-based targeted therapy for malignant brain tumors.Clin Dev Immunol 2012 (2012): 480429. https://doi.org/10.1155/2012/480429.
Chandramohan V, Sampson JH, Pastan I, Bigner DD. Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol. 2012;2012:480429.
Chandramohan, Vidyalakshmi, et al. “Toxin-based targeted therapy for malignant brain tumors.Clin Dev Immunol, vol. 2012, 2012, p. 480429. Pubmed, doi:10.1155/2012/480429.
Chandramohan V, Sampson JH, Pastan I, Bigner DD. Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol. 2012;2012:480429.

Published In

Clin Dev Immunol

DOI

EISSN

1740-2530

Publication Date

2012

Volume

2012

Start / End Page

480429

Location

Egypt

Related Subject Headings

  • Tumor Microenvironment
  • Survival Analysis
  • Recombinant Fusion Proteins
  • Proteomics
  • Prognosis
  • Precision Medicine
  • Molecular Targeted Therapy
  • Immunotoxins
  • Immunology
  • Humans